Translational imaging of apoptosis

Anti-Cancer Agents in Medicinal Chemistry

Volumn 9, Issue 9, 2009, Pages 958-967

  Smith, Graham ^a   Nguyen, Quang Dé ^a   Aboagye, Eric O ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Annexin V; Apoptosis; ApoSense; Caspase 3; DEVD; Isatin; PET

Indexed keywords

3 IODOBENZOYL I 124; 4 AMIDOCOUMARIN; 4 IODOBENZOYL I 124; 7 AMINO 4 METHYLCOUMARIN; AMINOLUCIFERIN; APOSENSE MOLECULE; CAMPTOTHECIN; CHEMICAL COMPOUND; COUMARIN DERIVATIVE; DANSYL ML 10; DYE; ETHYLENEDIAMMINE N,N' DIACETATE ANNEXIN 5 TC 99M; FLUORESCEIN ISOTHIOCYANATE; FLUORESCENT DYE; FLUORINE 18; FLUOROURACIL; HYDRAZINONICOTINAMIDE ANNEXIN 5 TC 99M; IODINE 123; IODINE 124; LIPOCORTIN 5; LUCIFERIN; ML 10 F 18; ML 10 H 3; N,N' DI DANSYL CYSTINE; NST 732; RADIOISOTOPE; SMALL MOLECULE COMPOUND; SODIUM IODIDE I 124; TECHNETIUM 99M; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACCURACY; APOPTOSIS; DEGENERATIVE DISEASE; DRUG DESIGN; DRUG EFFICACY; DRUG STRUCTURE; EVALUATION; EXPERIMENTAL MODEL; HEART INFARCTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; ISCHEMIA; MOLECULAR IMAGING; NONHUMAN; PATIENT CARE; QUALITY CONTROL; REPRODUCIBILITY; REVIEW; TREATMENT RESPONSE;

ANIMALS; APOPTOSIS; CASPASES; CELL LINE; CYSTEINE PROTEINASE INHIBITORS; DRUG DELIVERY SYSTEMS; HUMANS; PEPTIDES; POSITRON-EMISSION TOMOGRAPHY;

EID: 73449095414     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152009789377709     Document Type: Review

References (60)

1. Kerr, J.F.; Wyllie, A.H.; Currie, A.R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer, 1972, 26, 239-57.
2. Reed, J.C. Apoptosis-based therapies. Nat. Rev. Drug Disc., 2002, 1, 111-121.
3. Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell, 2000, 100, 57-70.
4. Blankenberg, F.G. In vivo detection of apoptosis. J. Nucl. Med., 2008, 49 (Suppl 2), 81S-95S.
5. Tait, J.F. Imaging of apoptosis. J. Nucl. Med., 2008, 49, 1573-6.
6. Martin, S.J.; Reutelingsperger, C.P.; McGahon, A.J.; Rader, J.A.; van Schie, R.C.; LaFace, D.M.; Green, D.R. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J. Exp. Med., 1995, 182, 1545-56.
7. Lahorte, C.M.M.; Vanderheyden, J-L.; Steinmetz, N.; Van de Wiele, C.; Dierckx, R.A.; Slegers, G. Apoptosis-detecting radioligands: current state of the art and future perspectives. Eur. J. Nucl. Med. Mol. Imaging, 2004, 31, 887-919.
8. Kemerink, G.J.; Liu, X.; Kieffer, D.; Ceyssens, S.; Mortelmans, L.; Verbruggen, A.M.; Steinmetz, N.D.; Vanderheyden, J-L.; Green, A.M.; Verbeke, K. Safety, biodistribution, and dosimetry of 99mTc-HYNIC-annexin V, a novel human recombinant annexin V for human application. J. Nucl. Med., 2003, 44, 947-52.
9. Abrams, M.J.; Juweid, M.; tenKate, C.I.; Schwartz, D.A.; Hauser, M.M.; Gaul, F.E.; Fuccello, A.J.; Rubin, R.H.; Strauss, H.W.; Fischman, A.J. Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. J. Nucl. Med., 1990, 31, 2022-8.
10. Dekker, B.; Keen, H.; Lyons, S.; Disley, L.; Hastings, D.; Reader, A.; Ottewell, P.; Watson, A.; Zweit, J. MBP-annexin V radiolabeled directly with iodine-124 can be used to image apoptosis in vivo using PET. Nucl. Med. Biol., 2005, 32, 241-52.
11. Keen, H.G.; Dekker, B.A.; Disley, L.; Hastings, D.; Lyons, S.; Reader, A.J.; Ottewell, P.; Watson, A.; Zweit, J. Imaging apoptosis in vivo using 124I-annexin V and PET. Nucl. Med. Biol., 2005, 32, 395-402.
12. Dekker, B.; Keen, H.; Shaw, D.; Disley, L.; Hastings, D.; Hadfield, J.; Reader, A.; Allan, D.; Julyan, P.; Watson, A.; Zweit, J. Functional comparison of annexin V analogues labeled indirectly and directly with iodine-124. Nucl. Med. Biol., 2005, 32, 403-13.
13. Collingridge, D.R.; Glaser, M.; Osman, S.; Barthel, H.; Hutchinson, O.; Luthra, S.K.; Brady, F.; Bouchier-Hayes, L.; Martin, S.J.; Workman, P.; Price, P.; Aboagye, E.O. In vitro selectivity, in vivo biodistribution and tumour uptake of annexin V radiolabelled with a positron emitting radioisotope. Br. J. Cancer, 2003, 89, 1327-1333.
14. Boersma, H.H.; Kietselaer, B.L.J.H.; Stolk, L.M.L.; Bennaghmouch, A.; Hofstra, L.; Narula, J.; Heidendal, G.A.K.; Reutelingsperger, C.P.M. Past, Present, and Future of Annexin A5: From Protein Discovery to Clinical Applications. J. Nucl. Med., 2005, 46, 2035-2050.
15. van Genderen, H.O.; Kenis, H.; Hofstra, L.; Narula, J.; Reutelingsperger, C.P. Extracellular annexin A5: functions of phosphatidyl-serine-binding and two-dimensional crystallization. Biochim. Biophys. Acta, 2008, 1783, 953-63.
16. 99mTc-labeled annexin V fragments: a potential SPECT radiopharmaceutical for imaging cell death. Nucl. Med. Biol., 2006, 33, 635-643.
17. Damianovich, M.; Ziv, I.; Heyman, S.N.; Rosen, S.; Shina, A.; Kidron, D.; Aloya, T.; Grimberg, H.; Levin, G.; Reshef, A.; Bentolila, A.; Cohen, A.; Shirvan, A. ApoSense: a novel technology for functional molecular imaging of cell death in models of acute renal tubular necrosis. Eur. J. Nucl. Med. Mol. Imaging, 2006, 33, 281-291.
18. Ziv, I.; Shirvan, A. Perturbed membrane-binding compounds and methods of using the same. WO 2005/067388, 2005.
19. Taylor, R.C.; Cullen, S.P.; Martin, S.J. Apoptosis: controlled demolition at the cellular level. Nat. Rev. Mol. Cell Biol., 2008, 9, 231-241.
20. Grimberg, H.; Levin, G.; Shirvan, A.; Cohen, A.; Yogev-Falach, M.; Reshef, A.; Ziv, I. Monitoring of tumor response to chemotherapy in vivo by a novel small-molecule detector of apoptosis. Apoptosis, 2009, 14, 257-267.
21. Reshef, A.; Shirvan, A.; Waterhouse, R.N.; Grimberg, H.; Levin, G.; Cohen, A.; Ulysse, L.G.; Friedman, G.; Antoni, G.; Ziv, I. Molecular imaging of neurovascular cell death in experimental cerebral stroke by PET. J. Nucl. Med., 2008, 49, 1520-1528.
22. Aloya, R.; Shirvan, A.; Grimberg, H.; Reshef, A.; Levin, G.; Kidron, D.; Cohen, A.; Ziv, I. Molecular imaging of cell death in vivo by a novel small molecule probe. Apoptosis, 2006, 11, 2089-2101.
23. Cohen, A.; Shirvan, A.; Levin, G.; Grimberg, H.; Reshef, A.; Ziv, I. From the Gla domain to a novel small-molecule detector of apoptosis. Cell Res., 2009, 19(5), 625-627.
24. Scaduto, R.C., Jr.; Grotyohann, L.W. Measurement of mitochondrial membrane potential using fluorescent rhodamine derivatives. Biophys. J., 1999, 76, 469-77.
25. Okada, H.; Mak, T.W. Pathways of apoptotic and non-apoptotic cell death in tumour cells. Nat. Rev. Cancer, 2004, 4, 592-603.
26. Nicholson, D.W.; Thornberry, N.A. Caspases: killer proteases. Trends Biochem. Sci., 1997, 22, 299-306.
27. Degterev, A.; Boyce, M.; Yuan, J. A decade of caspases. Oncogene, 2003, 22, 8543-8567.
28. Launay, S.; Hermine, O.; Fontenay, M.; Kroemer, G.; Solary, E.; Garrido, C. Vital functions for lethal caspases. Oncogene, 2005, 24, 5137-5148.
29. Earnshaw, W.C.; Martins, L.M.; Kaufmann, S.C. Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu. Rev. Biochem., 1999, 68, 383-424.
30. Woo, E.-J.; Kim, Y.-G.; Han, W.-D.; Shin, S.; Robinson, H.; Park, S.-Y.; Oh, B.-H. Structural mechanism for inactivation and activation of CAD/DFF40 in the apoptotic pathway. Mol. Cell, 2004, 14, 531-539.
31. Thornberry, N.A.; Rano, T.A.; Peterson, E.P.; Rasper, D.M.; Timkey, T.; Garcia-Calvo, M.; Houtzager, V.M.; Nordstrom, P.A.; Roy, S.; Vaillancourt, J.P.; Chapman, K.T.; Nicholson, D.W. A combinatorial approach defines specifities of members of the caspase family and granzyme B. J. Biol. Chem., 1997, 272, 17907-17911.
32. Garcia-Calvo, M.; Peterson, E.P.; Leiting, B.; Ruel, R.; Nicholson, D.W.; Thornberry, N.A. Inhibition of human caspases by peptide-based and macromolecular inhibitors. J. Biol. Chem., 1998, 273, 32608-32613.
33. Slee, E.A.; Zhu, H.; Chow, S.C.; MacFarlane, M.; Nicholson, D.W.; Cohen, G.M. Benzyloxycarbonyl-Val-Ala-Asp (OMe) fluoromethylketone (SZ-VAD-FMK) inhibits apoptosis by blocking the processing of CPP32. Biochem. J., 1996, 315, 21-24.
34. Liu, J.; Bhalgat, M.; Zhang, C.; Diwu, Z.; Hoyland, B.; Klaubert, D.H. Fluorescent molecular probes V: a sensitive caspase-3 substrate for fluorometric assays. Bioorg. Med. Chem. Lett., 1999, 9, 3231-6.
35. Cai, S.X.; Zhang, H.-Z.; Guastella, J.; Drewe, J.; Yang, W.; Weber, E. Design and synthesis of rhodamine 110 derivative and caspase-3 substrate for enzyme and cell-based fluorescent assay. Bioorg. Med. Chem. Lett., 2001, 11, 39-42.
36. Wang, Z.Q.; Liao, J.; Diwu, Z. N-DEVD-N′- morpholinecarbonylrhodamine 110: novel caspase-3 fluorogenic substrates for cell-based apoptosis assay. Bioorg. Med. Chem. Lett., 2005, 15, 2335-8.
37. O'Brien, M.A.; Daily, W.J.; Hesselberth, P.E.; Moravec, R.A.; Scurria, M.A.; Klaubert, D.H.; Bulleit, R.E.; Wood, K.V. Homogenous, bioluminescent protease assays: caspase-3 as a model. J. Biomol. Scr., 2005, 10, 137-148.
38. Suzuki, N.; Sato, M.; Okada, K.; Goto, T. Studies on firefly bioluminescence-1. Tetrahedron, 1972, 28, 4065-4074.
39. Bullok, K.; Piwnica-Worms, D. Synthesis and characterization of a small, membrane-permeant, caspase-activatable far-red fluorescent peptide for imaging apoptosis. J. Med. Chem., 2005, 48, 5404-5407.
40. Bullok, K.E.; Maxwell, D.; Kesarwala, A.H.; Gammon, S.; Prior, J.L.; Snow, M.; Stanley, S.; Piwnica-Worms, D. Biochemical and in vivo characterization of a small, membrane-permeant, caspase-activatable far-red fluorescent peptide for imaging apoptosis. Biochemistry, 2007, 46, 4055-4065.
41. Stefflova, K.; Chen, J.; Marotta, D.; Li, H.; Zheng, G. Photodynamic therapy agent with a built-in apoptosis sensor for evaluating its own therapeutic outcome in situ. J. Med. Chem., 2006, 49, 3850-3856.
42. Haberkorn, U.; Kinscherf, R.; Krammer, P.H.; Mier, W.; Eisenhut, M. Investigation of a potential scintigraphic marker of apoptosis: radioiodinated Z-Val-Ala-DL-Asp(O-methyl)-fluoromethyl ketone. Nucl. Med. Biol., 2001, 28, 793-798.
43. 131I-Labeled peptides as caspase substrates for apoptosis imaging. J. Nucl. Med., 2005, 46, 1066-1074.
44. Lee, D.; Long, S.A.; Murray, J.H.; Adams, J.L.; Nuttall, M.E.; Nadeau, D.P.; Kikly, K.; Winkler, J.D.; Sung, C.; Ryan, M.D.; Levy, M.A.; Keller, P.M.; DeWolf, W.E. Potent and selective non-peptide inhibitors of caspases 3 and 7. J. Med. Chem., 2001, 44, 2015-2026.
45. Lee, D.; Long, S.A.; Adams, J.L.; Chan, G.; Vaidya, K.S.; Francis, T.A.; Kikly, K.; Winkler, J.D.; Sung, C.; Debouck, C.; Richardson, S.; Levy, M.A.; DeWolf, W.E.; Keller, P.M.; Tomaszek, T.; Head, M.S.; Ryan, M.D.; Haltiwanger, R.C.; Liang, P.; Janson, C.A.; McDevitt, P.J.; Johanson, K.; Concha, N.O.; Chan, W.; Abdel-Meguid, S.S.; Badger, A.M.; Lark, M.W.; Nadeau, D.P.; Suva, L.J.; Gowen, M.; Nuttall, M.E. Potent and selective nonpeptide inhibitors of caspases 3 and 7 inhibit apoptosis and maintain cell functionality. J. Biol. Chem., 2000, 275, 16007-16014.
46. Chu, W.; Zhang, J.; Zeng, C.; Rothfuss, J.; Tu, Z.; Chu, Y.; Reichert, D.E.; Welch, M.J.; Mach, R.H. N-Benzylisatin sulfonamide analogues as potent caspase-3 inhibitors: Synthesis, in vitro activity, and molecular modeling studies. J. Med. Chem., 2005, 48, 7637-7647.
47. Kopka, K.; Faust, A.; Keul, P.; Wagner, S.; Breyholz, H.; Höltke, C.; Schober, O.; Schäfers, M.; Levkau, B. 5-Pyrrolidinylsulfonyl isatins as a potential tool for the molecular imaging of caspases in apoptosis. J.Med. Chem., 2006, 49, 6704-6715.
48. 18F-labeled isatin analog for imaging caspase-3 activation in apoptosis. Bioorg. Med. Chem. Lett., 2006, 16, 5041-5046.
49. 18F]fluoroethylazide. J. Med. Chem., 2008, 51, 8057-8067.
50. Chu, W.; Rothfuss, J.; d'Avignon, A.; Zeng, C.; Zhou, D.; Hotchkiss, R.S.; Mach, R.H. Isatin sulfonamide analogs containing a michael addition acceptor: a new class of caspase 3/7 inhibitors. J. Med. Chem., 2007, 50, 3751-3755.
51. Blankenberg, F.G. In vivo imaging of apoptosis. Cancer. Biol. Ther., 2008, 7, 1525-32.
52. Narula, J.; Acio, E.R.; Narula, N.; Samuels, L.E.; Fyfe, B.; Wood, D.; Fitzpatrick, J.M.; Raghunath, P.N.; Tomaszewski, J.E.; Kelly, C.; Steinmetz, N.; Green, A.; Tait, J.F.; Leppo, J.; Blankenberg, F.G.; Jain, D.; Strauss, H.W. Annexin-V imaging for noninvasive detection of cardiac allograft rejection. Nat. Med., 2001, 7, 1347-52.
53. Wang, Y.; Huang, J.C.; Zhou, Z.L.; Yang, W.; Guastella, J.; Drewe, J.; Cai, S.X. Dipeptidyl aspartyl fluoromethylketones as potent caspase-3 inhibitors: SAR of the P2 amino acid. Bioorg. Med. Chem. Lett., 2004, 14, 1269-72.
54. Graham, R.K.; Deng, Y.; Slow, E.J.; Haigh, B.; Bissada, N.; Lu, G.; Pearson, J.; Shehadeh, J.; Bertram, L.; Murphy, Z.; Warby, S.C.; Doty, C.N.; Roy, S.; Wellington, C.L.; Leavitt, B.R.; Raymond, L.A.; Nicholson, D.W.; Hayden, M.R. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell, 2006, 125, 1179-91.
55. Faust, A.; Wagner, S.; Law, M.P.; Hermann, S.; Schnockel, U.; Keul, P.; Schober, O.; Schafers, M.; Levkau, B.; Kopka, K. The nonpeptidyl caspase binding radioligand (S)-1-(4-(2-[18F]Fluoroethoxy)-benzyl)-5-[1-(2- methoxymethylpyrrolidinyl)sulfonyl]isatin ([18F]CbR) as potential positron emission tomography-compatible apoptosis imaging agent. Q. J. Nucl. Med. Mol. Imaging, 2007, 51, 67-73.
56. Kravchenko, D.V.; Kuzovkova, Y.A.; Kysil, V.M.; Tkachenko, S.E.; Maliarchouk, S.; Okun, I.M.; Balakin, K.V.; Ivachtchenko, A.V. Synthesis and structure-activity relationship of 4-substituted 2-(2-acetyloxyethyl)-8- (morpholine-4-sulfonyl)pyrrolo[3,4-c]quinoline-1,3-diones as potent caspase-3 inhibitors. J. Med. Chem., 2005, 48, 3680-3.
57. Kravchenko, D.V.; Kysil, V.V.; Ilyn, A.P.; Tkachenko, S.E.; Maliarchouk, S.; Okun, I.M.; Ivachtchenko, A.V. 1,3-Dioxo-4-methyl-2,3-dihydro-1H-pyrrolo[3, 4-c]quinolines as potent caspase-3 inhibitors. Bioorg. Med. Chem. Lett., 2005, 15, 1841-5.
58. Therasse, P.; Arbuck, S.G.; Eisenhauer, E.A.; Wanders, J.; Kaplan, R.S.; Rubinstein, L.; Verweij, J.; Van Glabbeke, M.; van Oosterom, A.T.; Christian, M.C.; Gwyther, S.G. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst., 2000, 92, 205-16.
59. Michaelis, L.C.; Ratain, M.J. Measuring response in a post-RECIST world: from black and white to shades of grey. Nat. Rev. Cancer, 2006, 6, 409-14.
60. Wahl, R.L.; Jacene, H.; Kasamon, Y.; Lodge, M.A. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J. Nucl. Med., 2009, 50, S122-S150.